Novo Nordisk stock slips again as Wegovy price cuts and CagriSema doubts weigh
Copenhagen, Feb 25, 2026, 13:46 CET — Regular session Novo Nordisk slipped roughly 1.7% to 239.5 Danish crowns on Wednesday. The shares continued to feel pressure after new U.S. pricing steps and lingering doubts about its upcoming obesity drug.